Antimicrobials News

The 2007 decision to no longer advise antibiotic prophylaxis to prevent viridans group streptococcal infective endocarditis in many patients with CVD having invasive dental procedures was correct, according to a new scientific statement.

Patients treated with isavuconazole as primary or salvage therapy for invasive fungal sinusitis experienced overall survival rates of 82% at 42 days and 70% at 84 days, according to study results published in Clinical Infectious Diseases.

Today, the FDA approved Tembexa to treat smallpox.

The FDA this week approved Scynexis’s novel 1-day oral treatment for vulvovaginal candidiasis, ibrexafungerp, making it the first approved drug in a novel antifungal class in more than 20 years, the company said.

Antibiotic use in the United States declined significantly from 1999 to 2018, though none of that decline occurred over the last decade despite a push for antimicrobial stewardship, researchers reported in Open Forum Infectious Diseases.

A large global study of urban microbiomes found that each city has its own “molecular echo.”

The results of a randomized controlled trial demonstrated that a 6-week course of antibiotics for prosthetic joint infection was not noninferior to a 12-week course and resulted in a higher percentage of patients with unfavorable outcomes.

The rate of hospital-acquired Clostridioides difficile infection improved by 39% at a Quebec hospital when 70% of antibiotic users took a three-strain Lactobacillus probiotic under a pharmacy-driven protocol, researchers reported.

The FDA granted priority review to maribavir for the treatment of patients with transplant-associated cytomegalovirus infection that was resistant or refractory to prior treatment, according to the agent’s manufacturer.

My career has been on the preventing infectious diseases side.